BCR and B-cell chronic lymphocytic leukemia: CLL therapy typically involves immunochemotherapy and, more recently, targeted inhibitors blocking pro-survival B cell receptor signaling (BCR, e.g., ibrutinib, idelalisib) or anti-apoptotic BCL2 signaling (venetoclax) [60].